Table 2:

Mean yearly rates of change in the CSF concentration of the five analytes under study resulting from the mixed-effects modeling and their differences among various subsets of study participants. P-values (unadjusted for multiplicity) are associated with the tests of the hypothesis that mean rate of change is equal to zero, or the hypothesis that the two rates of change estimated for two participant groups are the same.

		CMGA	FABPH	NPTX2	SCG2	VGF
Model 1	CN at baseline vs. zero	−0.01 ± 0.01	0.01 ± 0.01	−0.03 ± 0.02	−0.02 ± 0.01	−0.02 ± 0.02
	MCI at baseline vs. zero	−0.04 ± 0.01 *	0.02 ± 0.01 *	−0.08 ± 0.02 ‡	−0.02 ± 0.01	−0.04 ± 0.02 *
	CN vs. MCI at baseline	0.02 ± 0.01	0.01 ± 0.01	0.05 ± 0.02 *	0.01 ± 0.01	0.02 ± 0.02
Model 2	Ratio− at baseline vs. zero	−0.01 ± 0.01	0.02 ± 0.01	−0.03 ± 0.02	0 ± 0.01	−0.01 ± 0.02
	Ratio+ baseline vs. zero	−0.05 ± 0.01 †	0.02 ± 0.01	−0.09 ± 0.02 ‡	−0.04 ± 0.01 *	−0.06 ± 0.02 ‡
	Ratio+ vs. Ratio− at baseline	0.04 ± 0.01 †	0 ± 0.01	0.06 ± 0.02. †	0.03 ± 0.01 *	0.05 ± 0.02 ‡
Model 3	Non-progressors vs. zero	−0.02 ± 0.01	0.01 ± 0.01	−0.03 ± 0.02	−0.02 ± 0.01	−0.02 ± 0.02
	Progressors vs. zero	−0.05 ± 0.02 *	0.01 ± 0.02	−0.11 ± 0.02 ‡	−0.03 ± 0.02	−0.06 ± 0.02 *
	Progressors vs. Non-progressors	0.03 ± 0.02	0 ± 0.01	0.08 ± 0.02 ‡	0.01 ± 0.02	0.04 ± 0.02

CN: cognitively normal

MCI: mild cognitive impairment

Ratio+: participants with p-Tau₁₈₁ / Aβ_1–42 ≥ 0.025 [26]

Ratio−: participants with p-Tau₁₈₁ / Aβ_1–42 < 0.025 [26]

Progressors: participants who were initially diagnosed as CN (resp. MCI) and who were diagnosed within 4 years and 1 month after the initial diagnosis with MCI or dementia (resp. dementia)

^*)<0.05;

^†)<0.005;

^‡)<0.0005